|
CA3227103A1
(en)
|
2021-07-30 |
2023-02-02 |
Matthew P. GEMBERLING |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
US20240252684A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
GB2625500B
(en)
|
2021-09-21 |
2026-04-01 |
Scribe Therapeutics Inc |
Engineered CasX repressor systems
|
|
IL316722A
(en)
*
|
2022-05-01 |
2024-12-01 |
Chroma Medicine Inc |
Compositions and methods for epigenetic regulation of PCSK9 expression
|
|
GB2634837A
(en)
*
|
2022-06-07 |
2025-04-23 |
Scribe Therapeutics Inc |
Compositions and methods for the targeting of PCSK9
|
|
JP2025524455A
(ja)
*
|
2022-06-23 |
2025-07-30 |
エヌクロマ・バイオ，インコーポレーテッド |
Ｔｒａｃ発現のエピジェネティック調節のための組成物及び方法
|
|
IL317701A
(en)
*
|
2022-06-23 |
2025-02-01 |
Chroma Medicine Inc |
Epigenetic editing compositions and methods
|
|
EP4544058A1
(en)
*
|
2022-06-23 |
2025-04-30 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of ciita expression
|
|
IL317874A
(en)
|
2022-06-24 |
2025-02-01 |
Tune Therapeutics Inc |
Compounds, systems and methods for reducing low density lipoproteins through targeted gene suppression
|
|
CA3260110A1
(en)
|
2022-06-24 |
2023-12-28 |
European Molecular Biology Laboratory |
MODULAR TOOL BASED ON CRISPR FOR THE SPECIFIC INTRODUCTION OF EPIGENETIC MODIFICATIONS ON TARGET LOCI
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics, Inc. |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
KR20250077608A
(ko)
*
|
2022-08-19 |
2025-05-30 |
튠 쎄라퓨틱스, 인코포레이티드 |
표적 유전자 억제를 통한 b형 간염 바이러스 조절용 조성물, 시스템 및 방법
|
|
WO2024044574A1
(en)
*
|
2022-08-23 |
2024-02-29 |
The Regents Of The University Of California |
Compositions and methods for reducing ionizing radiation-induced hematopoietic stem cell damage
|
|
WO2024064642A2
(en)
|
2022-09-19 |
2024-03-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for modulating t cell function
|
|
IL319704A
(en)
*
|
2022-09-23 |
2025-05-01 |
Nchroma Bio Inc |
Compositions and methods for epigenetic regulation of HBV gene expression
|
|
WO2024081879A1
(en)
*
|
2022-10-14 |
2024-04-18 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of cd247 expression
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
KR20250165443A
(ko)
|
2023-02-17 |
2025-11-25 |
화이트헤드 인스티튜트 포 바이오메디칼 리서치 |
후성유전학적 변형 제조를 위한 조성물 및 방법
|
|
WO2024238321A1
(en)
*
|
2023-05-12 |
2024-11-21 |
Mammoth Biosciences, Inc. |
Compositions and methods for targeted epigenetic modification
|
|
AU2024270764A1
(en)
|
2023-05-15 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
WO2024238700A1
(en)
*
|
2023-05-15 |
2024-11-21 |
Chroma Medicine, Inc. |
Compositions and methods for epigenetic regulation of hbv gene expression
|
|
KR20260030105A
(ko)
*
|
2023-06-16 |
2026-03-05 |
에피제닉 테라퓨틱스 피티이 리미티드 |
B형 간염 바이러스 유전자를 표적으로 하는 후성유전학적 편집 도구
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
CN121909284A
(zh)
|
2023-07-31 |
2026-04-21 |
图恩疗法股份有限公司 |
用于调节il-2基因表达的组合物和方法
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025251019A1
(en)
*
|
2024-05-31 |
2025-12-04 |
Nchroma Bio, Inc. |
Compositions and methods for epigenetic editing
|
|
WO2025260068A1
(en)
|
2024-06-14 |
2025-12-18 |
Tune Therapeutics, Inc. |
Lipid nanoparticle formulation for delivery of nucleic acids to cells
|
|
WO2026015647A1
(en)
|
2024-07-09 |
2026-01-15 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for cell differentiation using targeted gene activation of dll4 and/or vcam1
|
|
WO2026064753A1
(en)
|
2024-09-23 |
2026-03-26 |
Tune Therapeutics, Inc. |
Dna methyltransferase-like protein (dnmt3l) or dna methyltransferase 3a (dnmt3a) repressor systems for epigenetic editing
|